Selexis SA, a JSR Life Sciences company, has named Roland Hoffmann-Hecht, Ph.D., as its new chief business officer. As a member of the company’s executive leadership team, Dr. Hoffmann-Hecht will be responsible for all corporate and business development activities and will report to Selexis Chief Executive Officer Dirk Lange.
 
Dr. Hoffmann-Hecht joined the company from Polpharma Biologics, where he was head of business development, CDMO Europe. Previously, he was chief customer officer at CDMO start-up biopharmaceuticals company, Halix B.V. Dr. Hoffmann-Hecht also brings expertise in CDMO services, business development, marketing and sales as senior director of business development and vice president of business development at BIOMEVA GmbH and CMC Biologics (both now part of AGC Biologics), respectively. He was also senior director of international sales at Rentschler Biotechnologie GmbH.
 
“We are fortunate to welcome Roland to our executive leadership team given his expansive career in contract development and manufacturing organizations (CDMOs) serving the biopharmaceuticals industry and demonstrated success building valuable relationships with partners,” said Mr. Lange. “His highly relevant skills and experience, coupled with his scientific and industry knowledge, will be invaluable to Selexis as we bolster our leading position in cell line development and ensure the continued success of our “Gene-to-GMP in 9 Months” and SKI (Selexis KBI Integrated) programs, which we offer in conjunction with fellow JSR Life Sciences affiliate company, KBI Biopharma.”